Literature DB >> 22470111

Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

Ashley D Hall1, Molly E Steed, Cesar A Arias, Barbara E Murray, Michael J Rybak.   

Abstract

Daptomycin MICs for enterococci are typically 1- to 2-fold higher than those for Staphylococcus aureus, and there is an imminent need to establish the optimal dose for appropriate treatment of enterococcal infections. We investigated the bactericidal activity of daptomycin at various dose exposures compared to that of linezolid against vancomycin-resistant enterococcus (VRE) in an in vitro pharmacokinetic/pharmacodynamic model utilizing simulated endocardial vegetations over 96 h. Daptomycin at doses of 6, 8, 10, and 12 mg/kg of body weight/day and linezolid at a dose of 600 mg every 12 h were evaluated against two clinical vancomycin-resistant Enterococcus faecium strains (EFm11499 and 09-184D1051), one of which was linezolid resistant (09-184D1051), and one clinical vancomycin-resistant Enterococcus faecalis strain (EFs11496). Daptomycin MICs were 4, 2, and 0.5 μg/ml for EFm11499, 09-184D1051, and EFs11496, respectively. Bactericidal activity, defined as a ≥ 3 log(10) CFU/g reduction from the initial colony count, was demonstrated against all three isolates with all doses of daptomycin; however, bactericidal activity was not sustained with the daptomycin 6- and 8-mg/kg/day regimens. Linezolid was bacteriostatic against EFm11499 and displayed no appreciable activity against 09-184D1051 or EFs11496. Concentration-dependent killing was displayed with more sustained reduction in colony count (3.58 to 6.46 and 5.89 to 6.56 log(10) CFU/g) at 96 h for the simulated regimen of daptomycin at doses of 10 and 12 mg/kg/day, respectively (P ≤ 0.012). No E. faecium mutants with reduced susceptibility were recovered at any dosage regimen; however, the E. faecalis strain developed reduced daptomycin susceptibility with daptomycin at 6, 8, and 10 but not at 12 mg/kg/day. Daptomycin displayed a dose-dependent response against three VRE isolates, with high-dose daptomycin producing sustained bactericidal activity. Further research is warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22470111      PMCID: PMC3370794          DOI: 10.1128/AAC.06439-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Pharmacokinetics and tissue penetration of linezolid following multiple oral doses.

Authors:  T Gee; R Ellis; G Marshall; J Andrews; J Ashby; R Wise
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Daptomycin dose-effect relationship against resistant gram-positive organisms.

Authors:  Raymond Cha; Richard G Grucz; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.

Authors:  R L Akins; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.

Authors:  A Louie; P Kaw; W Liu; N Jumbe; M H Miller; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Raymond Cha; Michael J Rybak
Journal:  Diagn Microbiol Infect Dis       Date:  2003-11       Impact factor: 2.803

6.  Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.

Authors:  A P Johnson; S Mushtaq; M Warner; D M Livermore
Journal:  Int J Antimicrob Agents       Date:  2004-10       Impact factor: 5.283

7.  Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium.

Authors:  K C Lamp; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 8.  Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.

Authors:  Helen W Boucher; George Sakoulas
Journal:  Clin Infect Dis       Date:  2007-08-01       Impact factor: 9.079

9.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

Authors:  Barry H Dvorchik; David Brazier; Michael F DeBruin; Robert D Arbeit
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more
  42 in total

1.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia.

Authors:  Nicholas S Britt; Emily M Potter; Nimish Patel; Molly E Steed
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 3.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

Review 4.  Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.

Authors:  Sebastiano Leone; Silvana Noviello; Silvano Esposito
Journal:  Infection       Date:  2015-09-01       Impact factor: 3.553

5.  Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.

Authors:  Razieh Kebriaei; Seth A Rice; Kyle C Stamper; Ravin Seepersaud; Cristina Garcia-de-la-Maria; Nagendra N Mishra; Jose M Miro; Cesar A Arias; Truc T Tran; Paul M Sullam; Arnold S Bayer; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 7.  A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

8.  Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review.

Authors:  Farnaz Foolad; Brandie D Taylor; Samuel A Shelburne; Cesar A Arias; Samuel L Aitken
Journal:  J Antimicrob Chemother       Date:  2018-09-01       Impact factor: 5.790

9.  Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model.

Authors:  Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Razieh Kebriaei; Jordan R Smith; Katherine Lev; T T Tran; Warren E Rose; Cesar A Arias; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

10.  Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.

Authors:  Celine Vidaillac; Susana Gardete; Ryan Tewhey; George Sakoulas; Glenn W Kaatz; Warren E Rose; Alexander Tomasz; Michael J Rybak
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.